Patents Assigned to Ablynx N.V.
  • POLYPEPTIDES AND POLYPEPTIDE CONSTRUCTS COMPRISING SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST VON WILLEBRAND FACTOR
    Publication number: 20150299301
    Abstract: The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.
    Type: Application
    Filed: March 26, 2015
    Publication date: October 22, 2015
    Applicant: Ablynx N.V.
    Inventor: Karen Silence
  • AMINO ACID SEQUENCES DIRECTED AGAINST CELLULAR RECEPTORS FOR VIRUSES AND BACTERIA
    Publication number: 20150299327
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. Nanobodies specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. Said amino acid sequences may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.
    Type: Application
    Filed: February 20, 2015
    Publication date: October 22, 2015
    Applicant: Ablynx N.V.
    Inventors: Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Dominique Schols, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot, Peter Verheesen
  • Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
    Patent number: 9156914
    Abstract: The present application relates to amino acid sequences that are directed against and/or that can specifically bind to metalloproteinases from the ADAM family, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences, and to methods of preparing the same.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: October 13, 2015
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard
  • Method for the production of variable domains
    Patent number: 9150640
    Abstract: The present invention provides methods for the expression and/or production of variable domains with a C-terminal extension that can be used for coupling of the variable domain to one or more further groups, residues or moieties. In the method of the invention a yield of at least 80% of variable domains with a cysteine containing C-terminal extension is obtained. Also variable domains are provided and polypeptides comprising one or more variable domains obtainable by the methods of the present invention, as well as compounds that comprise such variable domains and/or polypeptides coupled to one or more groups, residues or moieties.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: October 6, 2015
    Assignee: Ablynx N.V.
    Inventors: Hilde Stals, Veronique De Brabandere, Peter Schotte
  • AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM
    Publication number: 20150266958
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 24, 2015
    Applicant: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • AMINO ACID SEQUENCES DIRECTED AGAINST HER2 AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CANCERS AND/OR TUMORS
    Publication number: 20150232562
    Abstract: The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: January 8, 2015
    Publication date: August 20, 2015
    Applicant: Ablynx N.V.
    Inventors: Hilde Adi Pierrette Revets, Carlo Boutton, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • SINGLE VARIABLE DOMAIN ANTIBODIES AGAINST OX40L, CONSTRUCTS AND THERAPEUTIC USE
    Publication number: 20150218281
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Application
    Filed: December 31, 2014
    Publication date: August 6, 2015
    Applicant: ABLYNX N.V.
    Inventors: FRANK VERDONCK, SIGRID CORNELIS, STEPHANIE STAELENS
  • Nanobodies against tumor necrosis factor-alpha
    Patent number: 9067991
    Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: June 30, 2015
    Assignee: Ablynx N.V.
    Inventor: Els Anna Alice Beirnaert
  • Amino acid sequences directed against multitarget scavenger receptors and polypeptides
    Patent number: 9034325
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) multitarget scavenger receptors such as e.g. Lox-1, RAGE, CD36, SR-A1, SR-B1, galectin-1, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively).
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: May 19, 2015
    Assignee: Ablynx N.V.
    Inventors: Maria Joao Saraiva, Peter Vanlandschoot, Edward Dolk, Renee de Bruin
  • P2X7 RECEPTOR ANTAGONISTS AND AGONISTS
    Publication number: 20150133637
    Abstract: The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 14, 2015
    Applicant: Ablynx N.V.
    Inventors: Welbeck Owusu Danquah, Friedrich Nolte, Catelijne Stortelers, Toon Laeremans
  • Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
    Patent number: 9028816
    Abstract: The present invention relates to polypeptides and polypeptide constructs comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation.
    Type: Grant
    Filed: January 9, 2004
    Date of Patent: May 12, 2015
    Assignee: Ablynx N.V.
    Inventor: Karen Silence
  • MONOVALENT, BIVALENT AND TRIVALENT ANTI HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) NANOBODY CONSTRUCTS FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS
    Publication number: 20150118233
    Abstract: Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
    Type: Application
    Filed: September 29, 2014
    Publication date: April 30, 2015
    Applicant: Ablynx N.V.
    Inventors: Erik Depla, Catelijne Stortelers, Stephanie Staelens
  • BIOLOGICAL MATERIALS RELATED TO CXCR7
    Publication number: 20150110796
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 23, 2015
    Applicant: ABLYNX N.V.
    Inventors: FRANCIS DESCAMPS, MARIA GONZALEZ PAJUELO, PASCAL GERARD MERCHIERS, CATELIJNE STORTELERS, PETER VANLANDSCHOOT, PHILIPPE VAN ROMPAEY, MARTINE SMIT, REGORIUS LEURS, DAVID ANDRE BAPTISTE MAUSSANG-DETAILLE
  • SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
    Publication number: 20150110782
    Abstract: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.
    Type: Application
    Filed: October 31, 2014
    Publication date: April 23, 2015
    Applicant: Ablynx N.V.
    Inventors: Karen Silence, Marc Jozef Lauwereys, Hans De Haard
  • Amino acid sequences directed against cellular receptors for viruses and bacteria
    Patent number: 9005963
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. NANOBODIES specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: April 14, 2015
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Dominique Schols, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot, Peter Verheesen
  • Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
    Publication number: 20150093377
    Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.
    Type: Application
    Filed: September 4, 2014
    Publication date: April 2, 2015
    Applicant: Ablynx N.V.
    Inventors: Maria Gonzalez Pajuelo, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
  • Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
    Patent number: 8975382
    Abstract: The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: March 10, 2015
    Assignee: Ablynx N.V.
    Inventors: Hilde Adi Pierrette Revets, Carlo Boutton, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • STABILIZED SINGLE DOMAIN ANTIBODIES
    Publication number: 20150064182
    Abstract: The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.
    Type: Application
    Filed: August 13, 2014
    Publication date: March 5, 2015
    Applicant: Ablynx N.V.
    Inventors: Karen Silence, Marc Jozef Lauwereys, Torsten Dreier
  • Single variable domain antibodies against OX40L, constructs and therapeutic use
    Patent number: 8962807
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: February 24, 2015
    Assignee: Ablynx N.V.
    Inventors: Frank Verdonck, Sigrid Cornelis, Stephanie Staelens
  • Anti IL-6R polypeptides and compositions thereof
    Patent number: 8962805
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: February 24, 2015
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy